Literature DB >> 9333047

Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.

L J Lee1, B Hafkin, I D Lee, J Hoh, R Dix.   

Abstract

The effects of food and sucralfate on the pharmacokinetics of levofloxacin following the administration of a single 500-mg oral dose were investigated in a randomized, three-way crossover study with young healthy subjects (12 males and 12 females). Levofloxacin was administered under three conditions: fasting, fed (immediately after a standardized high-fat breakfast), and fasting with sucralfate given 2 h following the administration of levofloxacin. The concentrations of levofloxacin in plasma and urine were determined by high-pressure liquid chromatography. By noncompartmental methods, the maximum concentration of drug in serum (Cmax), the time to Cmax (Tmax), the area under the concentration-time curve (AUC), half-life (t1/2), clearance (CL/F), renal clearance (CLR), and cumulative amount of levofloxacin in urine (Ae) were estimated. The individual profiles of the drug concentration in plasma showed little difference among the three treatments. The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively). Sucralfate, which was administered 2 h after the administration of levofloxacin, appeared to have no effect on levofloxacin's disposition compared with that under the fasting condition. Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions. The mean t1/2, CL/F, CLR, and Ae values were similar among all three treatment groups. In conclusion, the absorption of levofloxacin was slightly delayed by food, although the overall bioavailability of levofloxacin following a high-fat meal was not altered. Finally, sucralfate did not alter the disposition of levofloxacin when sucralfate was given 2 h after the administration of the antibacterial agent, thus preventing a potential drug-drug interaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333047      PMCID: PMC164092     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.

Authors:  K H Moore; G J Yuen; R H Raasch; J J Eron; D Martin; P K Mydlow; E K Hussey
Journal:  Clin Pharmacol Ther       Date:  1996-05       Impact factor: 6.875

2.  Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.

Authors:  S C Chien; A T Chow; J Natarajan; R R Williams; F A Wong; M C Rogge; R K Nayak
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine.

Authors:  F A Wong; S J Juzwin; S C Flor
Journal:  J Pharm Biomed Anal       Date:  1997-03       Impact factor: 3.935

4.  Effect of sucralfate on absorption of norfloxacin and ofloxacin.

Authors:  P Lehto; K T Kivistö
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 5.  The influence of food on the absorption of antimicrobial agents.

Authors:  P G Welling; F L Tse
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

6.  Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.

Authors:  S C Chien; M C Rogge; L G Gisclon; C Curtin; F Wong; J Natarajan; R R Williams; C L Fowler; W K Cheung; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.

Authors:  S Laganière; R F Davies; G Carignan; K Foris; L Goernert; K Carrier; C Pereira; I McGilveray
Journal:  Clin Pharmacol Ther       Date:  1996-09       Impact factor: 6.875

8.  Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin.

Authors:  B Ledergerber; J D Bettex; B Joos; M Flepp; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers.

Authors:  T J Lubowski; C H Nightingale; K Sweeney; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more
  26 in total

1.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.

Authors:  Norio Yasui-Furukori; Takenori Takahata; Tsuyoshi Kondo; Kazuo Mihara; Sunao Kaneko; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

3.  Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.

Authors:  J Lettieri; R Vargas; V Agarwal; P Liu
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; U Schühly; J G Möller; H Delesen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone.

Authors:  Katie J Suda; Kevin W Garey; Larry H Danziger
Journal:  Pharm World Sci       Date:  2005-04

Review 7.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 9.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

Review 10.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.